secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0002007919-25-000003
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx secures $150M loan facility from Oxford Finance; $100M funded upfront
-----------------------------------------------------------------------------

- Loan and Security Agreement with Oxford Finance for up to $150M term loan; $100M funded on Jan 13, 2025.
- Remaining $50M available at Inhibrx's request and Lenders' sole discretion.
- Interest-only payments through Feb 2028; maturity Jan 1, 2030; rate = 1M SOFR + 5.61% (floor 4.34%).
- Issued warrants for 140,741 shares at $14.21/exercise price, representing 2% of initial $100M tranche.
- Proceeds provide strategic flexibility ahead of expected data readouts for INBRX-109 and INBRX-106 programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000003/0002007919-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000003/inhibrx-20250113.htm
  HTML page:      https://secwatch.observer/filing/0002007919-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer